JPRN-UMIN000002512已完成未知
Combined therapy with intravenous recombinant tissue plasminogen activator (rt-PA) and edaravone in the acute ischemic stroke patients within 3 hours of onset - Combined therapy with intravenous recombinant tissue plasminogen activator (rt-PA) and edaravone in the acute ischemic stroke patients within 3 hours of onset
Department of Stroke Medicine, Kawasaki Medical School0 个研究点目标入组 100 人开始时间: 2009年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Diffusion weighted imaging evidence of significant early ischemic change 2)Other exclusion criteria are same as Japan Alteplase Clinical Trial (J-ACT) (stroke 2006;37:1810) 3)exclusion criteria of edaravone administraion mentioned in the package insert. Serume creatinine concentration over 1.5mg/dl
研究者
相似试验
进行中（未招募）
不适用
Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas. - NHL-ZNS-RezidivThe aim of the study is the prospective verification of effectiveness and compatibility of a systemic therapy with CNS passable cytostatics (high-dose Methotrexat and Ifosfamide, and high-dose Cytarabine and Thiothepa) combined with an intrathecal Depocyte therapy, followed by a High-dose dose chemotherapy with Carmustine, Thiothepa and Etoposid and an autologous stem cell transplantation.EUCTR2006-006516-30-DECharité-Universitätsmedizin Berlin
已完成
不适用
Intravenous immunoglobulin therapy combined with Vitamins E and C for Kawasaki DiseaseKawasaki diseaseJPRN-UMIN000037134Fukuoka Children's Hospital Kawasaki disease center20
已完成
2 期
Alternative therapy using continuous intravenous administration of adrenomedullin for patients with inflammatory bowel diseaseinflammatory bowel diseaseJPRN-UMIN000003230First Department of Internal Medicine, Faculty of Medicine, University of Miyazaki10
招募中
3 期
Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patientschronic hepatitis type CJPRN-UMIN000005598Kyoto University Graduate School of Medicine Center for Genomic Medicine100
已完成
不适用
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularizatioSubfoveal type 2 choroidal neovascularizationJPRN-UMIN000016870agoya City University Graduate School of Medicine20